
    
      This is an open-label, non-randomised, multicentre, Phase I/II study to assess safety,
      pharmacokinetics (PK), and early signs of activity of L19-IL2 monotherapy.

      In the first part of the study, there will be 5 dose escalation steps in sequential cohorts
      of patients with advanced solid tumours. In the second part of the study, patients with
      advanced RCC will be given a fixed dose of L19IL2 at the RD.
    
  